ArticleFrontiers in oncology2024

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.

Nebojsa Skorupan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.